Livzon Pharmaceutical : Interim Report 2022

(A joint stock company incorporated in the People's Republic of China with limited liability) Stock Code: 1513

2022 INTERIM REPORT

* For identification purpose only

CONTENTS	FINANCIAL HIGHLIGHTS	3
	SECTION I
	IMPORTANT NOTICE AND DEFINITIONS	5
	SECTION II
	COMPANY PROFILE AND MAJOR FINANCIAL INDICATORS	11
	SECTION III
	MANAGEMENT DISCUSSION AND ANALYSIS	16
	SECTION IV
	CORPORATE GOVERNANCE	86
	SECTION V
	MAJOR EVENTS	91
	SECTION VI
	ENVIRONMENTAL AND SOCIAL RESPONSIBILITY	107
	SECTION VII
	CHANGES IN EQUITY AND SHAREHOLDERS	131
	SECTION VIII
	INFORMATION ON PREFERRED SHARES	143
	SECTION IX
	INFORMATION ON BONDS	144
	SECTION X
	FINANCIAL REPORT	145

LIST OF DOCUMENTS AVAILABLE FOR INSPECTION

1. Full text of the 2022 Interim Report of the Company signed by the legal representative.

1. The unaudited financial report for the six months ended 30 June 2022 of the Company prepared in accordance with the China Accounting Standards for Business Enterprises, which has been signed and sealed by the person-in-charge of the Company, the person-in-charge of the Company's accounting work and the person-in-charge of the accounting department (the head of the accounting department).

1. The original copies of all documents and announcements of the Company which have been disclosed to the public on the website designated by the CSRC during the Reporting Period.

(IV)	The English and Chinese versions of the 2022 Interim Report of the Company published on the website of the Hong
	Kong Exchanges and Clearing Limited.

2	Livzon Pharmaceutical Group Inc. Interim Report 2022

FINANCIAL HIGHLIGHTS

	Major financial indicators (RMB in millions)
1.08%			Same Period
		Last Year
6,235.53 6,302.57			Reporting Period

					-4.23%	13.73%	111.34%	-3.54%
					1,426.39	1,371.17
					1,062.48	1,017.55	920.07	1,046.42	1,322.57
					674.91
Operating income	Net profit attributable	Net profit after	Net cash flow from	Total profit
					to shareholders of	extraordinary gains or	operating activities
					the Company	losses attributable to
							shareholders of
							the Company

Basic earnings per share (RMB/share)	Diluted earnings per share (RMB/share)

-4.39%

1.14

1.09

		Same Period
		Last Year
-4.39%		Reporting Period

1.14

1.09

Composition of principal businesses (RMB in millions)

5.55%

346.04

7.86%

490.62

27.72%

1,729.34

1.45%

90.52

3.12%

194.65

Income of Principal

Businesses

Total

6,239.73

Chemical drug preparations

		Gastroenterology
		Gonadotropic hormones
28.54%		Psychiatry
	Anti-infection
1,780.51
	Other chemical drug
		preparations
		APIs and intermediates
		Traditional Chinese
21.54%		medicine preparations
1,344.05		Diagnostic reagents
		and equipment

4.23%

264.00

Livzon Pharmaceutical Group Inc. Interim Report 2022

3

FINANCIAL HIGHLIGHTS

	Unit: RMB in millions
Chemical drug preparations	Unit: RMB in millions

-8.16%

1,938.70

1,780.51

6.82%

1,344.05

1,258.19

					36.26%				-0.25%
					264.00
					193.75			195.13	194.65
	Previous Period Reporting Period	Previous Period Reporting Period	Previous Period Reporting Period	Previous Period Reporting Period
	Gastroenterology			Gonadotropic	Psychiatry		Anti-infection
			hormones
APIs and intermediates			Traditional Chinese			Diagnostic reagents and
		medicine preparations			equipment

18.26%1,729.34

1,462.31

610.26

-19.60%

-11.43%

490.62

390.68

346.04

Previous Period

Reporting Period

Previous Period

Reporting Period

Previous Period

Reporting Period

4	Livzon Pharmaceutical Group Inc. Interim Report 2022